Last Updated : August 15, 2019
Details
Generic Name:
eltrombopag
Project Status:
Not filed
Therapeutic Area:
Severe aplastic anemia
Manufacturer:
Novartis Pharmaceuticals Canada Inc.
Brand Name:
Revolade
Project Line:
Reimbursement Review
Project Number:
NS0007-000
Submission Type:
Non Submission
Fee Schedule:
N/A
Indications:
Severe aplastic anemia
Recommendation Type:
Canada’s Drug Agency is unable to recommend reimbursement as a submission was not filed by the manufacturer
Last Updated : August 15, 2019